Thursday, 15 October 2026European Markets

NORDIC NANOVECTOR Stock Drops By 29% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NORDIC NANOVECTOR (Oslo Børs Benchmark Index_GI: NANOV.OL) fell by a staggering 29.13% in 21 sessions from kr1.02 to kr0.72 at 13:42 EST on Wednesday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI is rising 0.2% to kr1,243.41, following the last session's upward trend.

NORDIC NANOVECTOR's last close was kr0.78, 95.04% below its 52-week high of kr15.78.

About NORDIC NANOVECTOR

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, NORDIC NANOVECTOR has a trailing twelve months EPS of kr-5.995.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -155.9%.

Volatility

NORDIC NANOVECTOR's last week, last month's, and last quarter's current intraday variation average was a negative 0.30%, a negative 1.18%, and a positive 3.56%.

NORDIC NANOVECTOR's highest amplitude of average volatility was 1.48% (last week), 2.65% (last month), and 3.56% (last quarter).

Yearly Top and Bottom Value

NORDIC NANOVECTOR's stock is valued at kr0.72 at 13:42 EST, way under its 52-week high of kr15.78 and above its 52-week low of kr0.67.

More news about NORDIC NANOVECTOR (NANOV.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com